Keros Therapeutics, Inc.
KROS
$14.38
$0.221.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 254,413.25% | 2,027.27% | 4,750.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 254,413.25% | 2,027.27% | 4,750.00% | -- | -- |
| Cost of Revenue | 27.32% | -30.92% | 44.19% | 24.53% | 23.05% |
| Gross Profit | 525.77% | 33.84% | -43.08% | -24.42% | -22.78% |
| SG&A Expenses | 1.83% | 17.13% | 7.35% | 13.15% | 32.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.91% | 20.81% | 36.40% | 22.11% | 24.95% |
| Operating Income | 413.59% | -14.64% | -35.53% | -22.02% | -24.73% |
| Income Before Tax | 467.62% | -13.62% | -34.27% | -20.67% | -20.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 444.32% | -14.37% | -34.27% | -20.67% | -20.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 444.32% | -14.37% | -34.27% | -20.67% | -20.42% |
| EBIT | 413.59% | -14.64% | -35.53% | -22.02% | -24.73% |
| EBITDA | 416.11% | -14.53% | -35.46% | -21.84% | -24.56% |
| EPS Basic | 402.94% | 14.58% | -5.97% | 1.07% | 4.27% |
| Normalized Basic EPS | 423.44% | 15.14% | -5.97% | 1.05% | 4.27% |
| EPS Diluted | 399.17% | 14.58% | -5.99% | 1.07% | 4.13% |
| Normalized Diluted EPS | 419.80% | 15.14% | -5.97% | 1.05% | 4.27% |
| Average Basic Shares Outstanding | 13.66% | 33.89% | 26.70% | 21.96% | 25.79% |
| Average Diluted Shares Outstanding | 14.95% | 33.89% | 26.70% | 21.96% | 25.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |